Abstract
Management of the National Drug Administration Through the Use of Biosimilar Medicines. Expenditures, Numbers of Reimbursed Packages and Shares of Biosimilar Products in the Infliximab Market a Year Prior to and a Year after the Introduction of the National Drug Policy 2018–2022
Reference21 articles.
1. 1. Al-Salama, Z. T. (2018). PF-06438179/GP1111: An Infliximab Biosimilar. BioDrugs, 32(6), 639-642. https://doi.org/10.1007/s40259-018-0310-5.
2. 2. Becciolini, A., Raimondo, M. G., Crotti, C., Agape, E., Biggioggero, M., & Favalli, E. G. (2017). A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: Focus on interchangeability. Drug Design, Development and Therapy, 11, 1969-1978. https://doi.org/10.2147/DDDT.S138515.
3. 3. Department of Drug Administration. (2019). Average cost of chosen substances by Department of Drug Administration of National Health Fund.
4. 4. European Medicines Agency. (2017). Biosimilars in the EU, Information guide for healthcare professionals.
5. 5. European Medicines Agency. (2019). Summary of product characteristics of Remicade. Retrieved form http://www.ema.europa.eu/docs/pl_PL/document_library/EPAR_-_Product_Information/human/000963/WC500037287.pdf.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献